🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Metastatic Biliary Tract Cancer

CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors NCT05733000Phase 21 site📍 Chicago Northwestern University · Tests: Biospecimen Collection, Computed Tomography, Devimistat, Fluorouracil, Gemcitabine Hydrochloride Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma NCT07780838Phase 21 site📍 Columbus Ohio State University Comprehensive Cancer Center · Tests: Biospecimen Collection, Cisplatin, Computed Tomography, Durvalumab, Gemcitabine First-line Trastuzumab, Gemcitabine, Cisplatin and Nivolumab in Advanced HER2- Positive Biliary Tract Cancer: a Multicenter, Open-label, Single-arm Phase Ib/II Trial (HERBOT) NCT05749900Phase 1, Phase 21 site📍 Seoul Yonsei University · Tests: Trastuzumab+Nivolumab+Gemcitabine+Cisplatin Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer NCT07392541Phase 1, Phase 21 site📍 Wuhan Tongji Hospital · Tests: Adebrelimab, Gemcitabine + Cisplatin, Simvastatin 20mg Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study NCT07405086Phase 41 site📍 Portland OHSU Knight Cancer Institute · Tests: Biospecimen Collection, Immune Checkpoint Inhibitor A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors NCT07277413Phase 123 sites📍 Goodyear📍 Phoenix📍 Duarte IDEAYA Biosciences · Tests: IDE892, IDE397 Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer NCT06467357Phase 3272 sites📍 Scottsdale📍 Tucson📍 Tucson AstraZeneca · Tests: Gemcitabine, Cisplatin, Durvalumab, Trastuzumab deruxtecan, Rilvegostomig A Phase 1 Study of LNCB74 in Advanced Solid Tumors NCT06774963Phase 114 sites📍 Newport Beach📍 Edgewood📍 Boston NextCure, Inc. · Tests: LNCB74 BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion NCT07594626Phase 1, Phase 21 site📍 Chicago Northwestern University · Tests: Biospecimen Collection, Computed Tomography, Pemetrexed, PRMT5 Inhibitor BMS-986504 Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor NCT05523947Phase 1, Phase 219 sites📍 Boston📍 Nashville📍 Adelaide Yuhan Corporation · Tests: YH32367 Combination Therapy of GCNT and Tislelizumab in Advanced Biliary Tract Cancer NCT06893380n/a1 site📍 Seongnam-si CHA University · Tests: Gemcitabine, Cisplatin, Nab-paclitaxel, and Tislelizumab. A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer NCT07450976Phase 22 sites📍 Beijing📍 Shanghai Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Tests: SHR-A1904 for Injection Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib as First-Line Therapy for Advanced HER2-Positive/HER2-Low Biliary Tract Cancer NCT07670273Phase 21 site📍 Beijing Peking Union Medical College Hospital · Tests: Trastuzumab Rezetecan, Adebrelimab, Lenvatinib A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors NCT06043466Phase 12 sites📍 Hangzhou📍 Hangzhou Chongqing Precision Biotech Co., Ltd · Tests: CEA-targeted CAR-T cells Integrated Cancer Repository for Cancer Research NCT02012699n/a42 sites📍 Greenwood Village📍 Manchester📍 Daytona Beach University of Nebraska Determination of Copper and Other Trace Elements in Serum Samples From Patients With Biliary Tract Cancers NCT06060990NA1 site📍 Ljubljana Institute of Oncology Ljubljana · Tests: trace elements A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors NCT05592626Phase 1, Phase 219 sites📍 Sacramento📍 Celebration📍 Miami Marengo Therapeutics, Inc. · Tests: STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere) Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio NCT05655949Phase 21 site📍 Boston Beth Israel Deaconess Medical Center · Tests: Gemcitabine, Cisplatin, Durvalumab, Yttrium-90 PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma NCT05286814Phase 21 site📍 Bethesda National Cancer Institute (NCI) · Tests: Dexamethasone, PDS01ADC, Intera 3000 Hepatic Artery Infusion Pump (HAIP), Floxuridine Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors NCT04900818Phase 121 sites📍 Orange📍 Aurora📍 Layfayette I-Mab Biopharma US Limited · Tests: TJ033721 (givastomig), TJ033721 (givastomig) , nivolumab, chemotherapy, TJ033721 (givastomig), chemotherapy, TJ033721 (… Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors NCT06975410Phase 1, Phase 24 sites📍 Seoul📍 Seoul📍 Seoul Yuhan Corporation · Tests: YH32364 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations NCT07610798Phase 1, Phase 21 site📍 Guangzhou Shenzhen Ionova Life Sciences Co., Ltd. · Tests: INV-8989 A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer NCT06778031Phase 22 sites📍 Harbin📍 Shanghai Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Tests: SHR-A1811, SHR-1316, SHR-8068 Prospective Cohort of Immune Checkpoint Inhibitor-induced Hepatitis NCT06864481n/a1 site📍 Montpellier University Hospital, Montpellier · Tests: Blood samples CDH17 CAR-T Therapy in Advanced Malignant Solid Tumors NCT06937567EARLY Phase 11 site📍 Hangzhou Zhejiang University · Tests: CDH17 CAR-T, FAST LACO-Stim CDH17 CAR-T A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies NCT07197554Phase 16 sites📍 Duarte📍 Newport Beach📍 Boston SEED Therapeutics, Inc. · Tests: ST-01156 mFOLFOX/mFOLFIRI vs. mFOLFOX in Advanced or Recurrent Biliary Tract Cancer Second-line NCT07062536Phase 211 sites📍 Busan📍 Daegu📍 Gangneung Seoul National University Bundang Hospital · Tests: Oxaliplatin, 5FU, leucovorin, Oxaliplatin, 5FU, leucovorin/Irinotecan , 5FU, leucovorin, Sintilimab Plus NALIRIFOX or Gemcitabine-Cisplatin as First-Line Treatment for Metastatic Biliary Tract Cancer NCT07831993Phase 21 site📍 Nanjing The Affiliated Nanjing Drum Tower Hospital of Nanjing Unive… · Tests: Sintilimab, Irinotecan Hydrochloride Liposome Injection (II), Oxaliplatin, Leucovorin, Fluorouracil A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer NCT06431490Phase 1, Phase 243 sites📍 Fuyang📍 Hefei📍 Hefei Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Phar… · Tests: TQB2102 for injection The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) NCT04585750Phase 1, Phase 276 sites📍 Irvine📍 La Jolla📍 Los Angeles PMV Pharmaceuticals, Inc · Tests: rezatapopt, pembrolizumab
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy